IGV-001 SNO 2026 clinical presentation
Imvax says additional Phase 2b IGV-001 data were accepted for SNO’s November 12–15, 2026 meeting. The personalized whole-tumor immunotherapy is being developed for newly diagnosed glioblastoma.
What matters
Track what the company has actually announced, the study or asset involved, and the evidence needed to confirm the milestone.
- September topline subgroup results are already disclosed; this is the later conference-presentation event, not an unreported positive trial result.
- Research candidate, not a live market, clinical probability, company equity or access to private shares.
Primary evidence
Confirmed meeting window: November 12–15, 2026; presentation day unconfirmed
Company context
Opened Vaxcyte 2026 DEF 14A. John Furey biography explicitly calls Imvax Inc. a privately held clinical-stage biotechnology company. Positive SEC-filed disclosure of director affiliation, not independent October 31 registry proof.
Potential outcome market
Will the accepted IGV-001 Phase 2b clinical data be publicly presented at SNO 2026?
This event is research, not a listed market. A market needs a precise question, resolution rules and liquidity before trading opens.